199 related articles for article (PubMed ID: 37033665)
21. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
22. Anti-tumor Necrosis Factor-Alpha Therapy and Hypoglycemia: A Real-World Pharmacovigilance Analysis.
Zhou Y; Xie W; Wang L; Zhu X; Li J; Liu L; Zhu S; Wang L
Drug Saf; 2022 Sep; 45(9):951-959. PubMed ID: 35857191
[TBL] [Abstract][Full Text] [Related]
23. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Wang F; Wu X
J Clin Pharm Ther; 2022 Oct; 47(10):1576-1584. PubMed ID: 35726369
[TBL] [Abstract][Full Text] [Related]
25. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
Kong W; Mao W; Zhang L; Wu Y
Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
[TBL] [Abstract][Full Text] [Related]
26. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS).
Huang J; Zhao Y; Cao Y; Zhang Q; Ran D; Li J; Luo L; Qiu F; Meng L
Int J Clin Pharm; 2022 Aug; 44(4):993-1003. PubMed ID: 35776375
[TBL] [Abstract][Full Text] [Related]
27. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
28. Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database.
Li H; Sun X; Sun D; Zhao J; Xu Z; Zhao P; Ma Z; Zhang Y
Int Immunopharmacol; 2021 Sep; 98():107818. PubMed ID: 34130149
[TBL] [Abstract][Full Text] [Related]
29. New onset inflammatory bowel disease in patient treated with secukinumab: Case report and review of literature.
Ali AK; Torosian A; Porter C; Bloomfeld RS; Feldman SR
Dermatol Ther; 2021 Nov; 34(6):e15151. PubMed ID: 34609037
[TBL] [Abstract][Full Text] [Related]
30. Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database.
Zheng Y; Guo X; Chen C; Chi L; Guo Z; Liang J; Wei L; Chen X; Ye X; He J
Br J Clin Pharmacol; 2023 Feb; 89(2):865-873. PubMed ID: 36106653
[TBL] [Abstract][Full Text] [Related]
31. Gastroenterological safety of IL-17 inhibitors: a systematic literature review.
Caron B; Jouzeau JY; Miossec P; Petitpain N; Gillet P; Netter P; Peyrin-Biroulet L
Expert Opin Drug Saf; 2022 Feb; 21(2):223-239. PubMed ID: 34304684
[TBL] [Abstract][Full Text] [Related]
32. Adenosine Deaminase as a Useful Biomarker for Diagnosis and Monitoring of Inflammatory Bowel Disease.
Yordanova M; Gerova D; Atanassova A; Galunska B
Clin Lab; 2020 Jul; 66(7):. PubMed ID: 32658411
[TBL] [Abstract][Full Text] [Related]
33. Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study.
Zhou Y; Chen M; Liu L; Chen Z
Diabetes Metab Syndr Obes; 2022; 15():155-163. PubMed ID: 35046686
[TBL] [Abstract][Full Text] [Related]
34. New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL study.
Letarouilly JG; Pham T; Pierache A; Acquacalda É; Banneville B; Barbarot S; Baudart P; Bauer É; Claudepierre P; Constantin A; Dernis E; Felten R; Gaudin P; Girard C; Gombert B; Goupille P; Guennoc X; Henry-Desailly I; Jullien D; Karimova E; Lanot S; Le Dantec L; Pascart T; Plastaras L; Sultan N; Truchet X; Varin S; Wendling D; Gaboriau L; Staumont-Sallé D; Peyrin-Biroulet L; Flipo RM
Rheumatology (Oxford); 2022 Jul; 61(7):2848-2855. PubMed ID: 34730790
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease.
Hohenberger M; Cardwell LA; Oussedik E; Feldman SR
J Dermatolog Treat; 2018 Feb; 29(1):13-18. PubMed ID: 28521565
[TBL] [Abstract][Full Text] [Related]
36. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
Jedlowski PM; Jedlowski MF; Fazel MT
Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
[TBL] [Abstract][Full Text] [Related]
37. The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases.
Țiburcă L; Bembea M; Zaha DC; Jurca AD; Vesa CM; Rațiu IA; Jurca CM
Curr Issues Mol Biol; 2022 Apr; 44(5):1851-1866. PubMed ID: 35678656
[TBL] [Abstract][Full Text] [Related]
38. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.
Menees SB; Powell C; Kurlander J; Goel A; Chey WD
Am J Gastroenterol; 2015 Mar; 110(3):444-54. PubMed ID: 25732419
[TBL] [Abstract][Full Text] [Related]
39. Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database.
Mettler C; Monnet D; Kramkimel N; Tréluyer JM; Mouthon L; Brézin A; Dupin N; Valnet-Rabier MB; Chouchana L; Terrier B
Ophthalmology; 2021 Dec; 128(12):1748-1755. PubMed ID: 34000304
[TBL] [Abstract][Full Text] [Related]
40. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]